CASI Pharmaceuticals, Inc. Operating Income Loss

Quick Answer

CASI Pharmaceuticals, Inc. reported Operating Income Loss of -$39.62 million for the year ending 2024.

  • CASI Pharmaceuticals, Inc. showed a decrease of -58.0% in Operating Income Loss from 2023 to 2024.
  • This data is from CASI Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
  • XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2024), CASI Pharmaceuticals, Inc.'s Operating Income Loss has grown by 24.9%.
  • Historical annual values: Fiscal year 2024: -$39.62 million | Fiscal year 2023: -$25.08 million | Fiscal year 2022: -$34.03 million | Fiscal year 2021: -$41.52 million | Fiscal year 2020: -$52.78 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: